Recommended Topic Related To:

Refludan

"Nov. 13, 2012 -- Transcendental Meditation is good for the heart, according to a new study.

The study was funded by the National Institutes of Health. It found that African-Americans with heart disease who regularly practiced TM reduc"...

Refludan

Refludan

SIDE EFFECTS

Adverse Events Reported in Clinical Trials in HIT Patients

The following safety information is based on all 198 patients treated with REFLUDAN (lepirudin) in the HAT-1 and HAT-2 studies. The safety profile of 113 REFLUDAN (lepirudin) patients from these studies who presented with TECs at baseline is compared to 91 such patients in the historical control.

Hemorrhagic Events. Bleeding was the most frequent adverse event observed in patients treated with REFLUDAN (lepirudin) . Table 4 gives an overview of all hemorrhagic events which occurred in at least two patients.

Table 4: Hemorrhagic Events*

  HAT-1 HAT-2 (All patients)
(n=198)
Patients with TECs
REFLUDAN
(n=113)
Historical control
(n=91)
Bleeding from puncture sites and wounds 14.1% 10.6% 4.4%
Anemla or Isolated drop in hemoglobin 13.1% 12.4% 1.1%
Other hematoma and unclassified bleeding 11.1% 10.6% 4.4%
Hematuria 6.6% 4.4% 0
Gastrointestinal and rectal bleeding 5.1% 5.3% 6.6%
Epistaxis 3.0% 4.4% 1.1%
Hemothorax 3.0% 0 1.1%
Vaginal bleeding 1.5% 1.8% 0
Intracranial bleeding 0 0 2.2%
*Patients may have suffered more than one event

Other hemorrhagic events (hemoperitoneum, hemoptysis, liver bleeding, lung bleeding, mouth bleeding, retroperi-toneal bleeding) each occurred in one individual among all 198 patients treated with REFLUDAN (lepirudin) .

Nonhemorrhagic events. Table 5 gives an overview of the most frequently observed nonhemorrhagic events.

Table 5: Nonhemorrhagic adverse events*

  HAT-1 HAT-2(All patients)
(n=198)
Patients with TECs
REFLUDAN
(n=113)
Historical control
(n=91)
Fever 6.1% 4.4% 8.8%
Abnormal Ilver function 6.1% 5.3% 0
Pneumonla 4.0% 4.4% 5.5%
Sepsis 4.0% 3.5% 5.5%
Allergic skin reactions 3.0% 3.5% 1.1%
Heart failure 3.0% 1.8% 2.2%
Abnormal kidney function 2.5% 1.8% 4.4%
Unspecified Infections 2.5% 1.8% 1.1%
Multiorgan fallure 2.0% 3.5% 0
Pericardlal effusion 1.0% 0 1.1%
Ventricular fibrillation 1.0% 0 0
* Patients may have suffered more than one event

Adverse Events Reported in Clinical Trials in Other Populations

The following safety information is based on a total of 2302 individuals who were treated with REFLUDAN (lepirudin) in clinical pharmacology studies (n = 323) or for clinical indications other than HIT (n = 1979).

Intracranial Bleeding

Intracranial bleeding was the most serious adverse reaction found in populations other than HIT patients. It occurred in patients with acute myocardial infarction who were started on both REFLUDAN (lepirudin) and thrombolytic therapy with rt-PA or streptokinase. The overall frequency of this potentially life-threat-ening complication among patients receiving both REFLUDAN (lepirudin) and thrombolytic therapy was 0.6% (7 out of 1134 patients). Although no intracranial bleeding was observed in 1168 subjects or patients who did not receive concomitant thrombolysis, there have been post marketing reports of intracranial bleeding with REFLUDAN (lepirudin) in the absence of concomitant thrombolytic therapy (see ADVERSE REACTIONS- Adverse Events from Post Marketing Reports and WARNINGS.)

Allergic Reactions

(See PRECAUTIONS.)

Allergic reactions or suspected allergic reactions in populations other than HIT patients include (in descending order of frequency*):

Airway reactions (cough, bronchospasm, stridor, dyspnea): Common
Unspecified allergic reactions: uncommon
Skin reactions (pruritus, urticaria, rash, flushes, chills): uncommon
General reactions (anaphylactoid or anaphylactic reactions): uncommon
Ederna (facial edema, tongue edema, larynx edema, angioedema): rare
The CIOMS (Council for International Organization of Medical Sciences) III standard categories are used for classification of freguencies:
very common 10% or more
common (frequent) 1 to < 10%
uncommon (infrequent) 0.1 to < 1%
rare 0.01 to < 0.1%
very rare 0.01% or less

About 53% (n = 46) of all allergic reactions or suspected aller-gic reactions occurred in patients who concomitantly received thrombolytic therapy (eg, streptokinase) for acute myocardial infarction and/or contrast media for coronary angiography.

Adverse Events from Post Marketing Reports

Serious anaphylactic reactions that have resulted in shock or death have been reported. (See PRECAUTIONS.)

Intracranial bleeding has been reported in patients treated with REFLUDAN (lepirudin) with or without concomitant thrombolytic therapy. (See WARNINGS.) Although no intracranial bleeding was observed in Clinical Trials in those patients who did not receive concomitant thrombolytic therapy (see Adverse Events Reported in Clinical Trials in HIT Patients and Adverse Events Reported in Clinical Trials in Other Populations below), there have been post marketing reports of intracranial bleeding in patients who received REFLUDAN (lepirudin) without concomitant throm-bolytic therapy.

Read the Refludan (lepirudin) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Concomitant treatment with thrombolytics (eg, rt-PA or strep-tokinase) may

  • increase the risk of bleeding complications
  • considerably enhance the effect of REFLUDAN (lepirudin) on aPTT prolongation.

(See also WARNINGS: Hemorrhagic Events, ADVERSE REACTIONS: Adverse Events Reported in Other Populations; Intracranial Bleeding and DOSAGE AND ADMINISTRATION: Monitoring and Adjusting Therapy; Concomitant Use With Thrombolytic Therapy.)

Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding (see also DOSAGE AND ADMINISTRATION: Monitoring and Adjusting Therapy; Use in Patients Scheduled for a Switch to Oral Anticoagulation).

Last reviewed on RxList: 7/31/2007
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Heart Health

Get the latest treatment options.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations